Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Allergan173 enrolled

Overview

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

173

Conditions

Eyelash Hypotrichosis

Interventions

bimatoprost solution 0.03%DRUG

One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

bimatoprost vehicle solutionDRUG

One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have inadequate eyelashes Exclusion Criteria: * Any disease/infection/abnormality of the eye or area around the eye * Any ocular surgery within 3 months or anticipated need for ocular surgery during the study * Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes * Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months * Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products * Use of treatments which may affect hair growth (eg, minoxidil, chemotherapy) within 6 months

Locations (1)

Unnamed facility

Tokyo, Japan

Outcomes

Primary Outcomes

Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)

The investigator evaluated the patient's eyelash prominence using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked at Baseline and Month 4. At least a 1-grade increase in the GEA score from Baseline indicated improvement.

Time frame: Baseline, Month 4

Secondary Outcomes

Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)

Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement).

Time frame: Baseline, Month 4

Change From Baseline in Eyelash Thickness as Measured by DIA

Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was assessed across both eyes as an average and is measured in millimeters squared (mm\^2). A positive change from Baseline indicated fuller eyelashes (improvement).

Time frame: Baseline, Month 4

Change From Baseline in Eyelash Darkness as Measured by DIA

Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).

Time frame: Baseline, Month 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.